FDA 483 - Sri Krishna Pharmaceuticals Limited - June 27, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA inspection of Sri Krishna Pharmaceuticals Limited in Hyderabad, India, uncovered significant deficiencies across quality control, process validation, and data integrity. The firm failed to reject contaminated components, concealed critical documents, and demonstrated systemic failures in investigating Out-of-Specification and Out-of-Trend results. These issues highlight a pervasive lack of adequate procedures and oversight, raising concerns about drug product quality and safety.
ID · 35c8f8b8-c6d7-42db-bc15-1103a9b10ebc